maryland physicians care
Medicaid with a Heart

PRIOR AUTHORIZATION REQUEST

Arcalyst

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for **ALL** PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

1	Will the requested medication be used in combination with another biologic agent for an inflammatory condition (for example, Cimzia, an etanercept product (Enbrel, biosimilars), an adalimumab product (Humira, biosimilars), Simponi (Aria or SC), an infliximab product (Remicade, biosimilars), Actemra (SC or IV), Kevzara, Orencia (SC or IV), a rituximab product (Rituxan, biosimilars), Kineret, Stelara (SC or IV), Siliq, Cosentyx, Taltz, Ilumya, Tremfya, Skyrizi, Entyvio)? [If yes, no further questions.]	Yes	No
2	What is the diagnosis or indication?		

PRIOR AUTHORIZATION REQUEST

[] Cryopyrin-Associated Periodic Syndromes (including familial cold autoinflammatory syndrome, Muckle- Wells Syndrome, and neonatal onset multisystem inflammatory disease or chronic infantile neurological cutaneous and articular syndrome) (If checked, go to 3)

[] Deficiency of interleukin-1 receptor antagonist (If checked, go to 9)

[] Pericarditis (If checked, go to 17)

[] All other indications or diagnoses (If checked, no further questions)

3	Is the patient currently receiving the requested medication? [If no, skip to question 7.]	Yes	No
4	Has the patient already received at least 6 months of therapy with the requested medication? [If no, skip to question 7.] [NOTE: Answer 'No' if the patient has received less than 6 months of therapy or if the patient is restarting therapy with the requested medication.]	Yes	No
5	When assessed by at least one objective measure, has the patient experienced a beneficial clinical response from baseline (prior to initiating the requested medication)? [If yes, no further questions.] [NOTE: Examples of objective measures include resolution of fever, improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers (for example, C-reactive protein, amyloid A), reduction in proteinuria, and/or stabilization of serum creatinine.]	Yes	No
6	Compared with baseline (prior to receiving the requested medication), has the patient experienced an improvement in at least one symptom, such as such as fewer cold-induced attacks, less joint pain/tenderness, stiffness, or swelling, decreased fatigue, improved function or activities of daily living? [No further questions.]	Yes	No
7	Is the patient greater than or equal to 12 year(s) of age? [If no, no further questions.]	Yes	No
8	Is the requested medication being prescribed by or in consultation with a rheumatologist, geneticist, allergist/immunologist, or dermatologist? [No further questions.]	Yes	No
9	Is the patient currently receiving the requested medication? [If no, skip to question 13.]	Yes	No
10	Has the patient already received at least 6 months of therapy with the requested	Yes	No

PRIOR AUTHORIZATION REQUEST

	medication? [If no, skip to question 13.]		
11	When assessed by at least one objective measure, has the patient experienced a beneficial clinical response from baseline (prior to initiating the requested medication)? [If yes, no further questions.] [NOTE: Examples of objective measures include improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers (for example, C-reactive protein, erythrocyte sedimentation rate), reduction in proteinuria, and/or stabilization of serum creatinine.]	Yes	No
12	Compared with baseline (prior to receiving the requested medication), has the patient experienced an improvement in at least one symptom, such as such as improvement of skin or bone symptoms, less joint pain/tenderness, stiffness, or swelling? [No further questions.]	Yes	No
13	Is the patient 10 kilograms (22 pounds) or greater? [If no, no further questions.]	Yes	No
14	Has genetic testing confirmed a mutation in the IL1RN gene? [If no, no further questions.]	Yes	No
15	Has the patient previously demonstrated a clinical benefit with Kineret (anakinra subcutaneous injection)? [If no, no further questions.] [NOTE: Examples of a clinical response with Kineret include normalized acute phase reactants; resolution of fever, skin rash, and bone pain; and reduced dosage of corticosteroids.]	Yes	No
16	Is the requested medication being prescribed by or in consultation with a rheumatologist, geneticist, dermatologist, or a physician specializing in the treatment of autoinflammatory disorders? [No further questions.]	Yes	No
17	Is the patient currently receiving the requested medication? [If no, skip to question 21.]	Yes	No
18	Has the patient been established on this medication for at least 3 months? [If no, skip to question 21.] [NOTE: Answer 'No' if the patient has received less than 90 days of therapy or if the patient is restarting therapy with the requested medication.]	Yes	No
19	When assessed by at least one objective measure, has the patient experienced a	Yes	No

PRIOR AUTHORIZATION REQUEST

	beneficial clinical response from baseline (prior to initiating the requested medication)? [If yes, no further questions.] [NOTE: Examples of objective measures include normalization of inflammatory biomarkers such as erythrocyte sedimentation rate and/or C-reactive protein, continued resolution of fever.]		
20	Compared with baseline (prior to receiving the requested medication), has the patient experienced an improvement in at least one symptom, such as resolution of chest pain or pericarditis pain? [No further questions.]	Yes	No
21	Is the patient greater than or equal to 12 year(s) of age? [If no, no further questions.]	Yes	No
22	Does the patient have recurrent pericarditis? [If no, no further questions.]	Yes	No
23	Prior to starting treatment with the requested medication, did the patient have a history of at least three episodes of pericarditis? [If no, no further questions.]	Yes	No
24	For the current episode, is the patient receiving standard treatment? [If yes, skip to question 26.] [NOTE: Standard treatments for pericarditis include nonsteroidal anti-inflammatory drug(s) [NSAIDs], colchicine, and/or systemic corticosteroids.]	Yes	No
25	Is standard treatment contraindicated? [If no, no further questions.] [NOTE: Standard treatments for pericarditis include nonsteroidal anti-inflammatory drug(s) [NSAIDs], colchicine, and/or systemic corticosteroids.]	Yes	No
26	Is the requested medication being prescribed by or in consultation with a cardiologist or rheumatologist?	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

PRIOR AUTHORIZATION REQUEST

SECTION B: Physician Signature

PHYSICIAN SIGNATURE DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250